Icra, Health News, ET HealthWorld


Indian pharma firms likely to see muted revenue growth from US generics market in FY23: Icra

Indian pharmaceutical corporations are prone to witness muted income development from the US generics market in FY23 as a consequence of value erosion strain, in line with rankings company Icra, The US has all the time been a key marketplace for Indian pharmaceutical corporations however over the previous few years, the revenues from there have grown at a comparatively modest tempo as a consequence of constant pricing strain, lack of main generic product launches and elevated regulatory scrutiny, Icra stated in a press release.

In FY22, the rankings company stated, the revenues from the US pharmaceutical marketplace for its pattern of eight main Indian pharmaceutical corporations declined marginally by 0.2 per cent owing to excessive single-digit to low-teens value erosion.

On the outlook, Icra vice chairman and co-group head Kinjal Shah stated, “Icra expects mid to high single-digit price erosion to continue to exert pressure over the near term, resulting in muted revenue growth for the Indian pharmaceutical companies from the US generics market in FY23.”

Further, she stated the influence of elevated uncooked materials costs and packaging prices along with comparatively greater freight charges and influence of provide chain disruptions on their margins will stay key monitorables.

Icra stated the COVID-19 pandemic had impacted the tempo of approvals of Abbreviated New Drug Applications (ANDA) and income development for corporations in FY21, whereas pricing pressures impacted development in FY22.

With the USFDA unable to conduct bodily inspections because of the pandemic-induced restrictions, each the tempo of ANDA approvals and issuance of warning letters to Indian pharmaceutical corporations have been decrease over the previous two years.

“However, the same is likely to pick up over the medium term as inspections gain traction,” it added.

Shah stated off late, Indian pharmaceutical corporations have reported sizeable provisioning and settlement pay-outs towards a few of the ongoing litigations, which have impacted their earnings and steadiness sheets to an extent.

“Indian pharmaceutical companies remain exposed to regulatory risks arising out of regular scrutiny by regulatory agencies including the US Food and Drug Administration (USFDA), the US Department of Justice and the Securities and Exchange Commission (SEC),” she added.

Most main corporations have varied ongoing litigations associated to patent claims, antitrust litigations and stay weak to any additional opposed developments on the identical, Shah stated.





Source hyperlink

Leave a Reply

Your email address will not be published.